AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 141 min read$MEDP

Troendle August J. sold $7.1M of MEDP

Troendle August J. (President & CEO) sold 11,824 shares of Medpace Holdings, Inc. (MEDP) at an average of $601.49 ($600.39–$601.53, $7.11M total) across 2 trades over 2026-08-12 to 2026-08-13.

Original reporting
SEC EDGAR · Troendle August J.
Published Aug 14, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MEDP
Neutral
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPNeutralLow
01

Why it matters

The disclosure updates the insider trading record and can influence short-term sentiment, but it does not include new business, financial, or regulatory information.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent company disclosures, but the article itself only adds the sale details.

03

What to watch

The filing does not provide the reason for sale, and the remaining holdings (603,978 shares) suggest the executive still retains a large position.

Relevance 6/10Novelty 5/10Timing: filed Aug 14 after-hours; reflects Aug 12-13 sales window

Background

This is an SEC Form 4 insider transaction by Medpace Holdings CEO and 10% owner Troendle August J.

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace CEO Troendle sold about 11,824 shares in Aug 12-13 open-market trades totaling $7.11M, per Form 4.

Expected impact

Likely limited, short-lived impact unless followed by additional disclosures or a pattern of sales.

Evidence & confidence

The filing discloses transaction size, dates, and that it was not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but there is no accompanying operational or guidance change.

Market effects

Sector

Minimal, as this is company-specific insider activity with no stated sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, and the absence of a stated 10b5-1 plan does not prove negative fundamentals.

Key entities

  • issuer
    Medpace Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Troendle August J.

    President and CEO, officer/director/10% owner who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min